Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WVI for Basal Ganglia Germ Cell Tumors
NCT05124951Phase 2Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Sep 2021
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in intracranial germ cell tumor (ICGCT), sponsored by Beijing Tiantan Hospital. Primary endpoints: Event-Free Survival at 3 years, Quality of Life (PedsQL 4.0) at 3 years and 2 more. Started Sep 2021; status: recruiting.
02
Conditions
intracranial germ cell tumor (ICGCT)
Beyond the preview
Go deeper on NCT05124951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05124951.